Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewPROTAC®(H-PGDS)-7 is a potent Degrader of hematopoietic prostaglandin D2 synthase (H-PGDS; DC50 = 17pM after 24 hours). Comprises the H-PGDS inhibitor TFC-007 (Cat. No. 5108) directly linked to E3 ligase cereblon. Suppresses prostaglandin D2 production in vitro and in vivo.
PROTAC®(H-PGDS)-8 negative control (Cat. No. 8005) also available.
PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
Sold under license from National Institute of Health Sciences, Japan and Tsuzuki Gakuen.
M. Wt | 742.79 |
Formula | C40H38N8O7 |
Storage | Store at -20°C |
Purity | ≥98% (HPLC) |
CAS Number | 2761281-50-7 |
PubChem ID | 162679258 |
InChI Key | KQNXUQJGOJWQGL-UHFFFAOYSA-N |
Smiles | O=C(C1=CN=C(OC2=CC=CC=C2)N=C1)NC3=CC=C(N4CCC(CC4)C(N5CCN(CC5)C(C=CC=C6C(N7C8C(NC(CC8)=O)=O)=O)=C6C7=O)=O)C=C3 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 74.28 | 100 |
The following data is based on the product molecular weight 742.79. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.35 mL | 6.73 mL | 13.46 mL |
5 mM | 0.27 mL | 1.35 mL | 2.69 mL |
10 mM | 0.13 mL | 0.67 mL | 1.35 mL |
50 mM | 0.03 mL | 0.13 mL | 0.27 mL |
References are publications that support the biological activity of the product.
Osawa et al (2023) CRBN ligand expansion for hematopoietic prostaglandin D2 synthase (H-PGDS) targeting PROTAC design and their in vitro ADME profiles. Bioorg.Med.Chem. 84 117259 PMID: 37018877
Murakami et al (2022) Structure-activity relationship study of PROTACs against hematopoietic prostaglandin D2 synthase. RSC Med.Chem. 13 1495 PMID: 36561070
Yokoo et al (2021) Discovery of a highly potent and selective Degrader targeting hematopoietic prostaglandin D synthase via in silico design. J.Med.Chem. 64 15868 PMID: 34652145
If you know of a relevant reference for PROTAC®(H-PGDS)-7, please let us know.
Keywords: PROTAC®(H-PGDS)-7, PROTAC®(H-PGDS)-7 supplier, PROTACHPGDS7, PROTAC, protacs, active, degrader, degraders, hematopoietic, prostaglandin, D2, synthase, cereblon, E3, ligase, proteolysis, targeting, chimera, HPGDS, Other, Synthases/Synthetases, Degraders, 8004, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for PROTAC®(H-PGDS)-7. Do you know of a great paper that uses PROTAC®(H-PGDS)-7 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review PROTAC®(H-PGDS)-7 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This brochure highlights the tools and services available from Bio-Techne to support your Targeted Protein Degradation and Induced Proximity research, including:
Degraders (e.g. PROTACs) are bifunctional small molecules, that harness the Ubiquitin Proteasome System (UPS) to selectively degrade target proteins within cells. They consist of three covalently linked components: an E3 ubiquitin ligase ligand, a linker and a ligand for the target protein of interest. Authored in-house, this poster outlines the generation of a toolbox of building blocks for the development of Degraders. The characteristics and selection of each of these components are discussed. Presented at EFMC 2018, Ljubljana, Slovenia